98%
921
2 minutes
20
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931077 | PMC |
http://dx.doi.org/10.3390/cancers16051045 | DOI Listing |
Electrophoresis
September 2025
Therapeutics Development and Supply-Analytical Development, Janssen Research & Development, LLC, Malvern, Pennsylvania, USA.
Monoclonal antibodies (mAbs) present analytical challenges due to their inherent heterogeneity and susceptibility to post-translational modifications (PTMs) during production and storage. Monitoring of charge heterogeneity profiles by imaged capillary isoelectric focusing (icIEF) has been aided by the use of non-detergent sulfobetaines (NDSBs), particularly NDSB-211, to enhance protein solubility and stability. When used in a quality control laboratory setting, NDSB-211 has shown performance variability over time due to residual manufacturing impurities that impact the capillary isoelectric focusing separation.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.
View Article and Find Full Text PDFCroat Med J
August 2025
Mehrdad Payandeh, Internal Medicine Department, School of Medicine, Kermanshah University of Medical Sciences, Beheshti Blvd, 83VX+PCM, Kermanshah, Iran,
Locally advanced renal cell carcinoma (RCC) presents significant therapeutic challenges, particularly in resource-limited settings with restricted access to new therapies. This report describes a new exploratory multimodal therapeutic approach for a patient with locally advanced clear cell RCC (ccRCC) with adrenal and lymph node metastases. A 45-year-old woman presented with an incidentally discovered 9-cm mass in the left kidney, which was later diagnosed as grade-2 ccRCC with adrenal and lymph node involvement.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study.
Virology
September 2025
Department of Medicine, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
View Article and Find Full Text PDF